GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » G.Barekat Pharm (XTEH:BRKT1) » Definitions » Purchase Of Investment

G.Barekat Pharm (XTEH:BRKT1) Purchase Of Investment : IRR Mil (TTM As of Mar. 2017)


View and export this data going back to 2017. Start your Free Trial

What is G.Barekat Pharm Purchase Of Investment?

G.Barekat Pharm's purchase of investment for the six months ended in Mar. 2017 was IRR0 Mil. It means G.Barekat Pharm spent IRR0 Mil on purchasing investments.

Compared with last quarter (IRR0 Mil in Mar. 2016 ), G.Barekat Pharm spent the same money on purchasing investments in Mar. 2017 (IRR0 Mil).


G.Barekat Pharm Purchase Of Investment Historical Data

The historical data trend for G.Barekat Pharm's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G.Barekat Pharm Purchase Of Investment Chart

G.Barekat Pharm Annual Data
Trend Mar16 Mar17
Purchase Of Investment
- -

G.Barekat Pharm Semi-Annual Data
Mar16 Mar17
Purchase Of Investment - -

G.Barekat Pharm Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.


G.Barekat Pharm Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of G.Barekat Pharm's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


G.Barekat Pharm (XTEH:BRKT1) Business Description

Traded in Other Exchanges
N/A
Address
No. 11, 5th Alley, Bucharest Avenue, Argentina Square, Tehran, IRN
G.Barekat Pharm focuses on the introduction of new pharmaceutical fields such as biotechnology, drug delivery which includes nanotechnology, slow release drugs, and new technologies for health, development of cellular molecular industries like tuberculosis, gene therapy, immunotherapy, and tissue technology.

G.Barekat Pharm (XTEH:BRKT1) Headlines

No Headlines